Information on the Total Number of Voting Rights

Negma Group has converted 580 convertible bonds in Oxurion resulting in a EUR 1,450,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment¹ that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5 billion.

Leuven, BELGIUM, Boston, MA, US – October 28, 2022 – 07.00 PM CET – In accordance with article 15 of the Belgian Act of May 2, 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Oxurion NV (Euronext Brussels: OXUR) (the “Company” or “Oxurion”), announces the below information, following the issuance of (i) 909,090 new ordinary shares on October 12, 2022, for a total amount of EUR 100,000, as the result of the conversion of 40 class A convertible bonds, (ii) 4,750,000 new ordinary shares on October 12, 2022, for a total amount of EUR 332,500, as the result of the conversion of 133 class B convertible bonds, (iii) 5.857.142 new ordinary shares on October 19, 2022, for a total amount of EUR 410,000, as the result of the conversion of 164 class B convertible bonds, (iv) 5,000,000 new ordinary shares on October 24, 2022, for a total amount of EUR 300,000, as the result of the conversion of 120 class B convertible bonds, and (v) 6,150,000 new ordinary shares on October 26, 2022, for a total amount of EUR 307,500, as the result of the conversion of 123 class B convertible bonds, all pursuant to the Capital Commitment entered into with Negma Group.

Following completion of the capital increase through the conversion of the convertible bonds, the total number of shares issued by Oxurion amounts to 77,825,765 outstanding ordinary shares carrying voting rights (compared to 55,159,533 outstanding ordinary shares previously). This number will be used as the denominator for the calculation of the percentages of…